drugset

Drugs / Medialipide

Follow last change Jan 2025 re-read 2 minutes ago

Medialipide

also known as Medialipide 20% · soybean oil (SO)-based IVFE

Other / unclassified

Developed for: end stage renal failure
Investigated by: Hospices Civils de Lyon

Trials 1 · a red edge is where a trial was stopped

today NCT06595680 · Ph 2

202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06595680	Jan 2025 → Jan 2027 expected	end stage renal failure, hemolytic anemia	Hospices Civils de Lyon	Not yet recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT02550860 Comparator	Jan 2015 → Sep 2017	intestinal disorder	Hospices Civils de Lyon	Terminated	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Medialipide	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06595680 ↗ 1 NCT02550860 ↗
Known as	Medialipide 20%	“Medialipide® 20% (Braun) is an emulsion of medium chain triglycerides (MCT) (6 to 12 carbons) used in parenteral nutrition.” NCT06595680 ↗
Known as	soybean oil (SO)-based IVFE	“soybean oil (SO)-based IVFE (Medialipide)” NCT02550860 ↗
Modality	Other / unclassified	“soybean oil (SO)-based IVFE” NCT02550860 ↗
Route	Intravenous	“intravenous fat emulsions (IVFE)” NCT02550860 ↗